Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Belgium

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences and healthcare business. We work with and have established long-term relationships with the top 100 lifesciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences and healthcare sectors. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need specialist advice in the area of lifesciences and healthcare for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
26 November 2015
Lifes­ci­ences & Health­care
Why CMS? Sec­tor spe­cial­istsStrong ex­pert­ise and high-qual­ity ad­vice de­livered from ded­ic­ated law­yers work­ing along­side sec­tor spe­cial­ists in­clud­ing sci­ent­ists, aca­dem­ics, reg­u­lat­ory, anti-cor­rup­tion...
05 September 2019
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With more than 300 law­yers, pat­ent at­tor­neys, sci­ent­ists and aca­dem­ics’ across CMS and the sup­port of the Life Sci­ences Asia-Pa­cific Net­work (LAN), we un­der­stand the sci­entif­ic and com­mer­cial as well...

Feed

Show only
24 February 2021
COV­ID and ViCo: EPO re­fer­ral to the En­larged Board of Ap­peal
In the last year, the COV­ID-19 pan­dem­ic has res­ul­ted in a large pro­por­tion of the leg­al sec­tor trans­ition­ing to a ‘work from home’ ar­range­ment, with meet­ings tak­ing place re­motely. Non-es­sen­tial travel...
16 February 2021
Fight­ing poor med­ic­a­tion ad­her­ence in the European Uni­on: The Grav­it­ate-Health...
Nowadays, European cit­izens can ob­tain a great amount of in­form­a­tion (on­line and off­line) about any medi­cine. However, this in­form­a­tion is in many cases un­re­li­able and dif­fi­cult to un­der­stand, en­cour­aging...
11 February 2021
New EPO Guidelines now pub­lished re­gard­ing amend­ing the de­scrip­tion: what’s...
In­tro­duc­tion In Oc­to­ber 2020, CMS pub­lished an art­icle ‘New EPO Guidelines ex­pec­ted re­gard­ing amend­ing a de­scrip­tion: what’s all the fuss about?’, which has been the cata­lyst for dis­cus­sion in the...
13 January 2021
EU­'s Por­tuguese pres­id­ency re­leases new draft of ePri­vacy Reg­u­la­tion
On 5 Janu­ary 2021, the Coun­cil of the EU – with Por­tugal serving as the Pres­id­ent-in-Of­fice – re­leased a new draft ver­sion of the ePri­vacy Reg­u­la­tion, which is meant to re­place the ePri­vacy Dir­ect­ive...
16 December 2020
EU Com­mis­sion pub­lishes pro­posed Data Gov­ernance Reg­u­la­tion
On 25 Novem­ber 2020 the European Com­mis­sion pro­posed new rules on data gov­ernance – a pro­posed Data Gov­ernance Reg­u­la­tion, which is the first of a set of meas­ures an­nounced in the 2020 European strategy...
15 December 2020
Five years after Hua­wei ZTE FRAND li­cens­ing ob­lig­a­tions again be­fore the...
On 26 Novem­ber 2020, the Düs­sel­dorf Re­gion­al Court an­nounced that it would sus­pend a pat­ent in­fringe­ment pro­ceed­ing and refer key ques­tions on com­puls­ory li­cens­ing of stand­ard es­sen­tial pat­ents (SEP)...
03 December 2020
With the in­tro­duc­tion of a new Phar­ma­ceut­ic­al Strategy for Europe, the...
New Phar­ma­ceut­ic­al Strategy to be a corner­stone of the European Health Uni­on The new Phar­ma­ceut­ic­al Strategy for Europe, an­nounced by the EU Com­mis­sion on 25 Novem­ber, is ex­pec­ted to be­come a main pil­lar...
01 December 2020
EPO pri­or­ity claim en­ti­tle­ment – the “same ap­plic­ants” ap­proach up­held
In a Press Com­mu­niqué dated 6 Novem­ber 2020, the EPO sum­mar­ises the Tech­nic­al Board of Ap­peal 3.3.08 writ­ten de­cision re­cently is­sued in case T 844/18 con­firm­ing the re­voc­a­tion of a pat­ent re­lated to...
24 November 2020
Schrems II: Re­sponses to the su­per­vis­ory au­thor­it­ies' as­sess­ment and re­com­mend­a­tions...
"Schrems II": Opin­ions of the su­per­vis­ory au­thor­it­ies on Schrems II and re­com­mend­a­tions on the im­ple­ment­a­tion of the judge­ment in in­ter­na­tion­al data trans­fers On 16 Ju­ly 2020, the Court of Justice of...
23 November 2020
EU high court con­firms CBD is not a nar­cot­ic
In a long-awaited rul­ing, the European Court of Justice (ECJ) cla­ri­fied that the can­nabis act­ive in­gredi­ent Can­na­bi­d­i­ol (CBD) is not to be clas­si­fied as a nar­cot­ic. France sub­mits ques­tion on CBD in e-ci­gar­ettes...
19/11/2020
CMS Bel­gi­um and CMS France ad­vised Biogroup in con­nec­tion with the ac­quis­i­tion...
CMS Bel­gi­um and CMS France ad­vised Biogroup in con­nec­tion with the ac­quis­i­tion of the Bel­gian clin­ic­al lab Group CMA-Med­ina. With this ac­quis­i­tion, the largest private clin­ic­al blood ana­lys­is groups in...
16 November 2020
Schrems II re­vis­ited: the European data au­thor­ity pub­lishes draft guid­ance...
On 11 Novem­ber 2020, the European Data Pro­tec­tion Board (EDPB) pub­lished two re­com­mend­a­tions that provide guid­ance to com­pan­ies on how to as­sess data trans­fers after the ECJ’s Schrems II de­cision:...